Covid-19 roundup: Eu­rope is ‘weeks away’ from remde­sivir de­ci­sion; John Far­ley gets per­ma­nent gig as chief of FDA di­vi­sion steer­ing pan­dem­ic re­sponse

Gilead’s remde­sivir — the first drug shown to ben­e­fit Covid-19 pa­tients in a ran­dom­ized, con­trolled tri­al set­ting — is po­ten­tial­ly a hop, skip and a jump away …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.